RE:Future ValueVenture,
ONCY's price languishes for complex and long standing reasons, but at present come down to expectations. People expect the price to vary around the current level and the ATM keeps it around that level.
Competitive pressures among big pharma potential acquirers can help over come the market myopia and market failure that confronts ONCY.
As I noted earlier, an equity partnership for, say, one third of the company equity and exclusive partnership on trials and marketing would immediately raise our market cap.
Also, the people who have to be convinced that ONCY is worth several billion are the boards of big pharma. The understand their competitive pressures and the need to avoid the patent cliff more than anyone else.
Finally if you read the broad strategic plans of companies like Roche or Bayer or Pfizer, it is as if they wrote those plans with ONCY in mind.
There will be events,such as as AA announcement (which would mean we start marketing) or an equity purchase and partnership that will raise the price enough to get ONCY an eventual big buy-out.
The vast market inefficiency cannot go on forever, when our clincial results are considered and the market for aquisitions is in the state reported here.